BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study Review Abstract Purpose: This review assesses the rationale, emerging clinical evidence, safety considerations, and practical implications of Bruton tyrosine kinase (BTK) degraders in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), particularly after
Tag: chronic lymphocytic leukemia
BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment
BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment Please like and subscribe if you enjoyed this video :-) Introduction The treatment landscape for chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries, has undergone a major shift with the advent of Bruton’s tyrosine kinase
